Adjuvant chemotherapy versus chemoradiation in high‐risk pancreatic adenocarcinoma: A propensity score‐matched analysis
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2491
Abstract: The American Society of Clinical Oncology guidelines recommend adjuvant chemoradiation (ACR) for margin‐positive (R1) and/or node‐positive (N+) pancreatic cancers. Our goal was to investigate if there is evidence of superiority of adjuvant chemoradiation (ACR) over… read more here.
Keywords: adjuvant chemotherapy; versus chemoradiation; chemotherapy versus; chemoradiation high ... See more keywords
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac188
Abstract: Abstract Objective First-line pembrolizumab with/without chemotherapy versus chemotherapy was evaluated in programmed death ligand 1 combined positive score ≥1, locally advanced/unresectable or metastatic gastric cancer/gastrooesophageal junction cancer in the KEYNOTE-062 study. We present results for… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; chemotherapy versus; pembrolizumab ... See more keywords
Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14664
Abstract: This meta‐analysis aimed to compare the efficacy of immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line therapy for patients with programmed death ligand‐1 (PD‐L1)‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer (NSCLC). read more here.
Keywords: meta analysis; combined chemotherapy; chemotherapy versus; versus chemotherapy ... See more keywords
Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7064
Abstract: 7064Background: The AZA-001 trial has shown a survival advantage for patients with high-risk MDS treated with HMA as compared to IC. However, this study was conducted mainly in an older population.... read more here.
Keywords: versus hypomethylating; chemotherapy versus; intensive chemotherapy; hypomethylating agents ... See more keywords
First-line chemotherapy versus chemoradiation for resectable distal esophageal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.331
Abstract: 331Background: Multiple randomized controlled trials have shown that both neoadjuvant chemotherapy (CT) and chemoradiation (CRT) convey survival benefit as compared to upfront surgery in patients w... read more here.
Keywords: chemotherapy; first line; versus chemoradiation; chemotherapy versus ... See more keywords